US 11,780,909 B2
Methods of treating viral infections by administering an antibody preparation comprising IGG, IGA and IGM
Wolfgang Möller, Oberursel (DE); Dieter Rudnick, Dreieich (DE); Oliver Maneg, Bad Homburg (DE); Michael Rodemer, Rodgau (DE); Matthias Germer, Langen (DE); and Veit Braun, Mainz (DE)
Assigned to BIOTEST AG, Dreieich (DE)
Filed by BIOTEST AG, Dreieich (DE)
Filed on Feb. 5, 2021, as Appl. No. 17/168,848.
Application 17/168,848 is a division of application No. 16/029,781, filed on Jul. 9, 2018, granted, now 10,954,290, issued on Mar. 23, 2021.
Application 16/029,781 is a division of application No. 15/348,121, filed on Nov. 10, 2016, granted, now 10,059,759, issued on Aug. 28, 2018.
Application 15/348,121 is a division of application No. 14/529,400, filed on Oct. 31, 2014, granted, now 9,518,110, issued on Dec. 13, 2016.
Application 14/529,400 is a division of application No. 13/655,686, filed on Oct. 19, 2012, granted, now 8,900,806, issued on Dec. 2, 2014.
Application 13/655,686 is a continuation of application No. PCT/EP2011/056487, filed on Apr. 21, 2011.
Claims priority of application No. 1006753 (GB), filed on Apr. 22, 2010.
Prior Publication US 2021/0179694 A1, Jun. 17, 2021
Int. Cl. C07K 16/12 (2006.01); A61K 39/395 (2006.01); A61K 47/18 (2017.01); C07K 16/06 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); C07K 16/14 (2006.01); C07K 1/30 (2006.01)
CPC C07K 16/1275 (2013.01) [A61K 9/0019 (2013.01); A61K 39/395 (2013.01); A61K 39/39591 (2013.01); A61K 47/183 (2013.01); C07K 16/065 (2013.01); C07K 16/121 (2013.01); C07K 16/125 (2013.01); C07K 16/1232 (2013.01); C07K 16/1267 (2013.01); C07K 16/14 (2013.01); A61K 2039/507 (2013.01); C07K 1/30 (2013.01); C07K 2317/21 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A method of treatment of a patient suffering from a viral infection comprising administering an antibody preparation to said patient wherein the antibody preparation comprises immunoglobulins IgG, IgA and IgM, wherein at least 15% by weight of the total immunoglobulins are IgM, at least 5% by weight of the total immunoglobulins are IgA and at least 40% by weight of the total immunoglobulins are IgG, wherein the antibody preparation is virus safe with respect to enveloped and non-enveloped virus, has an anticomplementary activity of ≤1 CH 50/mg protein, is stable in liquid form for at least 2 years when stored at 2 to 8° C., wherein the antibody preparation comprises a protein concentration of 40 g/L to 80 g/L, and an immunoglobulin content of greater than 95% of the total protein content.